Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Accumulated Expenses (2019 - 2025)

Immunocore Holdings' Accumulated Expenses history spans 4 years, with the latest figure at $219.7 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 18.44% year-over-year to $219.7 million; the TTM value through Dec 2025 reached $219.7 million, up 18.44%, while the annual FY2025 figure was $219.7 million, 18.44% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $219.7 million at Immunocore Holdings, up from $144.9 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $219.7 million in Q4 2025 and bottomed at $5.5 million in Q1 2024.
  • The 4-year median for Accumulated Expenses is $144.4 million (2025), against an average of $137.5 million.
  • The largest YoY upside for Accumulated Expenses was 2039.6% in 2025 against a maximum downside of 26.51% in 2025.
  • A 4-year view of Accumulated Expenses shows it stood at $76.7 million in 2022, then skyrocketed by 56.14% to $119.8 million in 2023, then soared by 54.82% to $185.5 million in 2024, then increased by 18.44% to $219.7 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Accumulated Expenses are $219.7 million (Q4 2025), $144.9 million (Q3 2025), and $143.8 million (Q2 2025).